|
USE OF ADENINE-DERIVED COMPOUNDS FOR THE TREATMENT OF LUPUS |
|
Principal Investigator: Claire LUGNIER
|
|
CONTEXT
Since the eighties, we have been collaborating with JJ Bourguignon
(University of Strasbourg) performing structure-activity relationships on
purified PDE1 to PDE5 (based on rolipram and trequinsin structures) to conceive
specific PDE4 inhibitors (>1000 original compounds) and we have studied PDE
implications in intracellular signalling in cardiovascular function and more
recently in angiogenesis. Some findings
were patented by Neuro3D/CNRS/University and lastly sold to Via Pharmaceuticals
Inc.,
San Francisco,
U.S.A. Among the not patented and
optimized PDE4 inhibitors compounds, we have studied NCS 613 and its analogues
as anti-inflammatory drugs and published some data. Therefore, we wondered to know
whether the optimized adenine analogue, NCS 613, might be helpful in autoimmune
diseases and investigated its in vivo
effects on a systemic
lupus erythematosus (SLE) mouse model.
Pour lire la suite, merci de vous identifier ou de vous inscrire dans la zone de droite... |
